(Amlodipine besylate + irbesartan) is a Small Molecule owned by Sumitomo Chemical, and is involved in 3 clinical trials, which were completed.

Amlodipine is a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. It inhibits the calcium ions (extracellular calcium) entering the cell (myocardial and peripheral vascular smooth muscle cells) through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance.


Irbesartan antagonizes angiotensin II by blocking AT1 receptors. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking in a non competitive manner. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure.

The revenue for (Amlodipine besylate + irbesartan) is expected to reach a total of $12m through 2023. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Amlodipine besylate + irbesartan) NPV Report.

(Amlodipine besylate + irbesartan) is currently owned by Sumitomo Chemical. Sumitomo Pharma is the other company associated in development or marketing of (Amlodipine besylate + irbesartan).

(Amlodipine besylate + irbesartan) Overview

Amlodipine besylate and irbesartan (Aimix) is a fixed dose combination acts as anti-hypertensive preparation. Aimix is formulated as film coated tablets for oral route of administration. Aimix is indicated for the treatment of hypertension.

Sumitomo Pharma Overview

Sumitomo Pharma, a subsidiary of Sumitomo Chemical Co Ltd develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. It also offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Dainippon has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY560,035 million for the fiscal year ended March 2022 (FY2022), an increase of 8.5% over FY2021. In FY2022, the company’s operating margin was 10.8%, compared to an operating margin of 13.8% in FY2021. In FY2022, the company recorded a net margin of 10.1%, compared to a net margin of 10.9% in FY2021. The company reported revenues of JPY159,413 million for the second quarter ended September 2022, a decrease of 0.3% over the previous quarter.

Quick View – (Amlodipine besylate + irbesartan)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Amlodipine besylate + irbesartan)
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.